Cytokinetics Earnings Outlook

0 Comments 1 view(s)

Cytokinetics (NASDAQ: CYTK) announces its next round of earnings Thursday. Here is Benzinga’s everything-that-matters guide for today’s Q4 earnings announcement.

Earnings and Revenue

Sell-side analysts are expecting Cytokinetics’s loss per share to be near 70 cents on sales of $6.32 million.

read more